Live Breaking News & Updates on Professorof Medicine
Stay updated with breaking news from Professorof medicine. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Idorsia initiates the Phase 3 registration study with selatogrel for the treatment of acute myocardial infarction pharmiweb.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from pharmiweb.com Daily Mail and Mail on Sunday newspapers.
Idorsia Pharmaceuticals Ltd: Idorsia initiates the Phase 3 registration study with selatogrel for the treatment of acute myocardial infarction Idorsia to host an investor webcast to discuss the Phase 3 study today at 14:30hrs CEST Allschwil, Switzerland - June 2 , 2021 Idorsia Ltd (SIX: IDIA) today announced the initiation of the Phase 3 registration study SOS-AMI to evaluate the efficacy and safety of self-administered subcutaneous selatogrel, Idorsia s P2Y 12 receptor antagonist, in suspected acute myocardial infarction (AMI). An AMI, or heart attack, is a life-threatening condition that occurs when blood flow to the heart muscle (myocardium) is suddenly decreased or completely cut off by a blood clot in one or more of the coronary vessels. An AMI requires immediate treatment, as any delay in intervention can result in irreversible damage to the heart muscle and adverse clinical outcomes. According to the US Centers for Disease Control and Prevention, e ....
and Chair of the Steering Committee for SOS-AMI, commented: P2Y 12 receptor antagonists have been used in the treatment of millions of patients globally, and their safety and efficacy profiles are well established. Despite the success of chronic treatment with this class and other effective interventions, patients are still suffering recurrent heart attacks. The idea for patients to self-inject early in the onset of symptoms is truly innovative. The subcutaneous route of administration could overcome the onset delay observed with oral compounds from the same class. To be effective, any antithrombotic treatment for use at the onset of AMI symptoms should be rapidly absorbed and potent, acting quickly to inhibit thrombus formation at an early stage. Inhibition should be reversed after a few hours to avoid interfering with later patient management decisions. It must also have an appropriate safety profile for use prior to formal diagnosis of AMI. Selatogrel has the ....
MacroBusiness Access Subscriber Only Content An open letter from a global coalition of eminent global scientists: Reaction to the China-WHO joint study team report CoV-2 origin hypotheses.”Having read the report entitled‘WHO-convenedGlobalStudy of Origins of SARS-CoV-2: China part’ and reviewed the statements made in the March 30, 2021 WHO-organized press event announcing the report’s release, we have regrettably concluded that our concerns were fully justified. In addition to the issues regarding the joint mission structure and process outlined in our previous open letter, we wish to express the following concerns regarding the joint study process and report conclusions: The joint study team saw its priority as seeking a zoonotic origin, not as fully examining all possible sources of the pandemic. Its Terms of Reference did not mention any possible lab-pathway and on the contrary explicitly stated a strict zoonosis origin from the very start (“id ....